SIGLEC1 Antibody

1. SIGLEC1 mRNA levels have potential as a novel predictive biomarker for Graves disease relapse. PMID: 29037117
2. classical HIV-1 infectious routes may compensate for the lack of Siglec-1 in fuelling HIV-1 dissemination within infected individuals PMID: 27510803
3. Our findings evidenced for the first time the novel association between SIGLEC1 rs3859664 SNP and active pulmonary TB. Intriguingly, carriers of the polymorphism produced less IL-1ss than non-carriers, suggesting the possible involvement of Siglec-1 signalling pathway with inflammasome complex. PMID: 28964857
4. the antibody-sialidase conjugate desialylated tumor cells in a HER2-dependent manner, reduced binding by natural killer (NK) cell inhibitory sialic acid-binding Ig-like lectin (Siglec) receptors, and enhanced binding to the NK-activating receptor natural killer group 2D (NKG2D). PMID: 27551071
5. The results reveal marked differences between afferent and efferent ymphatic endothelial cells and identify molecules on lymphatic vessels. Further characterizations of Siglec-1 (CD169) and macrophage scavenger receptor 1 (MSR1/CD204), show that they are discriminatively expressed on lymphatic endothelium of the subcapsular sinus but not on lymphatic vasculature of the lymphatic sinus PMID: 27601677
6. High CD169 expression is associated with HIV-1. PMID: 28794041
7. CD169 expression in regional LNs was not associated with PSA-relapse. PMID: 28880401
8. These results highlight the importance of sialic acids on the V1V2 region in binding to sialic acid-binding immunoglobulin-like lectin. PMID: 26667473
9. High expression of SIGLEC1 in pregnant women with autoantibodies against Ro/SS-A indicates an enhanced risk for autoimmune congenital heart block development. PMID: 28501799
10. These data demonstrate a prominent role for Siglec-1 in the internalization of HIV-1 to the virus-containing compartment in infected monocyte-derived macrophages PMID: 28129379
11. this study shows that binding of monoclonal antibodies to Sn results in delayed and reduced phagocytosis of fluorescent beads, and that no effect is observed on Fc-mediated phagocytosis or phagocytosis of bacteria by macrophages PMID: 27993350
12. These findings suggest that CD169+ macrophages in RLNs might be a useful marker for assessing clinical stage, including LN states, in patients with breast cancer. PMID: 27861544
13. CD169 might act as a co-stimulatory molecule for cytotoxic T-cell activation, and could define a population of tumour-infiltrating macrophages with potential anti-tumour properties in human hepatocellular carcinoma tissues. PMID: 27174787
14. In colorectal tumor, malignant melanoma, and endometrial tumor, it was shown that a high density of CD169-positive macrophages in the lymph node sinus was a predictive factor for better clinical prognosis. PMID: 28002629
15. Siglec-1 and Siglec-2 are potential biomarkers in autoimmune disease. (Review) PMID: 26752092
16. Siglec-1 on myeloid cells could fuel novel CD4(+) T-cell infections and contribute to HIV-1 dissemination in vivo. PMID: 25947229
17. evidence identifying sialyllactose-containing gangliosides in the viral membrane and the cellular lectin Siglec-1 as critical determinants for HIV-1 capture and storage by mature DCs and for DC-mediated trans-infection of T cells PMID: 25033082
18. Our study suggests that HIV-1 capture by CD169 can provide virus evasion from both innate (phagocytosis) and adaptive immune responses PMID: 25760631
19. GM3-CD169 binding is a gp120-independent signal for sequestration and preservation of HIV-1 infectivity. PMID: 24947940
20. The most abundant cytokine present in semen (TGF-beta1) is able to enhance specifically the expression of an important molecule (CD169) involved in the capture and transmission of HIV-1 particles from the mucosal lumen to the submucosal compartment. PMID: 25354152
21. Siglec-1 may play a proinflammatory role in stimulating lymphocyte proliferation and activation in rheumatoid arthritis. PMID: 24196391
22. CD169(+) macrophages in RLNs promote CD8(+) T-cell-mediated antitumor immunity. PMID: 23734742
23. downregulation of CD169 expression or neutralizing CD169 function abrogated dendritic cell-mediated HIV-1 capture and trans infection, while exogenous expression of CD169 in receptor-naive cells rescued glycosphingolipid-dependent capture and trans infection. PMID: 23593001
24. Based on increased SIGLEC1 expression in circulating monocytes, findings suggest a role for SIGLEC1 in the chronic progressive phases of multiple sclerosis. PMID: 22933622
25. the CD169/Sn endocytic pathway is conserved and capable of presenting lipid antigens to iNKT cells PMID: 23610394
26. These findings identify Siglec-1 as a key factor for HIV-1 spread via infectious dendritic/T-cell synapses. PMID: 23271952
27. Monocytes overexpress sialoadhesin nonspecifically during intestinal transplant rejection and systemic or enteritic inflammatory states. PMID: 22249367
28. Increased expression in monocytes of patients with primary biliary cirrhosis PMID: 20653431
29. Sialoadhesin is induced to high levels on CD14(+) cells early after HIV-1 infection in vivo. PMID: 17330143
30. Data show that the combinatorial signal delivered by R-DC to T cells via B7-H1 and sialoadhesin is crucial for the induction of IL-35(+) Treg. PMID: 19950173
31. Inhibitory signals delivered from human rhinovirus HRV14-treated dendritic cells to cocultured T cells via sialoadhesin (Sn) are critical for induction of T-cell anergy. PMID: 16002716
32. Increased expression of Siglec-1 in circulating systemic sclerosis (SSc) monocytes and tissue macrophages suggests type I IFN-mediated activation of monocytes occurs in SSc, possibly through toll-like receptor (TLR) activation of interferon secretion. PMID: 17328080
33. Siglec-1 (sialic acid binding Ig-like lectin 1) expression in resident blood monocytes is a potential biomarker for monitoring disease activity, displaying type I IFN responses, and estimating levels of anti-dsDNA antibodies PMID: 18383365
34. Increased sialoadhesin expression on CD14(+) monocytes occurs in response to HIV-1 infection with maximum expression associated with high viral load PMID: 18414664
35. Siglec-1 may be considered as a potential non-invasive indicator for monitoring disease severity and a biomarker for predicting the relative risk of cardiovascular events. PMID: 19285973
36. SIGLEC1, used as a surrogate marker for type I interferon, is a potential biomarker to assess disease acitvity in systemic lupus erythematosus (SLE). SIGLEC1+ resident monocytes could act as antigen presenting cells in SLE. PMID: 18383365

Show More

Hide All

HGNC: 11127

OMIM: 600751

KEGG: hsa:6614

STRING: 9606.ENSP00000341141

UniGene: Hs.31869